VIVS VivoSim Labs, Inc.
$0.28▼ -5.57%
Healthcare
Other
After hours
$0.28▼ -0.74%
Sep 11, 7:54 PM ET
Volume 385.6K
Avg Volume (10D) 503.5K
Key Metrics & Fundamentals
Market Cap
$3.79M
P/E Ratio
0.5
Div Yield
–%
52W Range
0.26 - 5.30
% vs 50 MA
-36.05%
% vs 200 MA
-79.83%
RSI-14
34.4
MACD Histogram
+0.0200
Beta (1Y vs SPY)
1.38
Free Cash Flow
-$3.24M
Gross Rev
$18,000
Gross Profit
$18,000
EBITDA
-$2.69M
COGS
–
Operating Exp
$2.78M
Operating Income
-$2.76M
EBIT
-$2.76M
Pretax Income
-$1.34M
Net Income
-$1.34M
EPS (Diluted)
-0.25
Price & Volume History
Loading chart…
Recent News
VivoSim Labs to Add Rat Liver Model to NAMkind Platform
GlobeNewswire · Sep 1, 2026 12:05 PM
VivoSim: Fiscal Q1 Earnings Snapshot
Associated Press · Aug 12, 2026 9:52 PM
BC-Most Active Stocks
Associated Press · Aug 7, 2026 2:30 PM
VivoSim Provides Financial and Listing Compliance Update
GlobeNewswire · Aug 6, 2026 12:05 PM
VivoSim Reports First Commercial Sales in China for NAMkind Testing Services (NASDAQ:VIVS)
InvestorsHub · Jul 21, 2026 2:28 PM
VivoSim Enters China Market With Initial Preclinical Testing Contracts
MT Newswires · Jul 21, 2026 1:35 PM
VivoSim Enters China with First Commercial Sales of NAMkind™ Toxicology Screening and Efficacy Testing Services
GlobeNewswire · Jul 21, 2026 12:05 PM
VivoSim Labs Prices $4 Million Private Placement of Stock, Warrants; Shares Fall Pre-Bell
MT Newswires · Jul 16, 2026 1:19 PM
VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor
GlobeNewswire · Jul 16, 2026 12:30 PM
VivoSim Receives $5 Million Milestone Payment From Eli Lilly and Forecasts 500%+ FY2027 Revenue Growth
InvestorsHub · Jul 15, 2026 2:46 PM
Financial Overview - Income Statement
Quarterly
Jun 2026
See VIVS's money flow as a full page
Social Sentiment
No Reddit posts found for VIVS.
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.